These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28442261)

  • 1. Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action.
    Nishida H; Arikawa Y; Hirase K; Imaeda T; Inatomi N; Hori Y; Matsukawa J; Fujioka Y; Hamada T; Iida M; Nishitani M; Imanishi A; Fukui H; Itoh F; Kajino M
    Bioorg Med Chem; 2017 Jul; 25(13):3298-3314. PubMed ID: 28442261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of pyrrole derivatives to find an effective potassium-competitive acid blocker with moderately long-lasting suppression of gastric acid secretion.
    Nishida H; Fujimori I; Arikawa Y; Hirase K; Ono K; Nakai K; Inatomi N; Hori Y; Matsukawa J; Fujioka Y; Imanishi A; Fukui H; Itoh F
    Bioorg Med Chem; 2017 Jul; 25(13):3447-3460. PubMed ID: 28483454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
    Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).
    Arikawa Y; Nishida H; Kurasawa O; Hasuoka A; Hirase K; Inatomi N; Hori Y; Matsukawa J; Imanishi A; Kondo M; Tarui N; Hamada T; Takagi T; Takeuchi T; Kajino M
    J Med Chem; 2012 May; 55(9):4446-56. PubMed ID: 22512618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KFP-H008 blocks gastric acid secretion through inhibiting H
    Li CY; Su M; Yan YY; Zhou L; Ao LY; Fang WR; Li YM
    Eur J Pharmacol; 2017 Sep; 810():112-119. PubMed ID: 28629736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
    Hori Y; Imanishi A; Matsukawa J; Tsukimi Y; Nishida H; Arikawa Y; Hirase K; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility.
    Takahashi N; Take Y
    J Pharmacol Exp Ther; 2018 Feb; 364(2):275-286. PubMed ID: 29180359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
    Echizen H
    Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.
    Scott DR; Munson KB; Marcus EA; Lambrecht NW; Sachs G
    Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1315-26. PubMed ID: 26423447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel 5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives as potent potassium-competitive acid blockers.
    Wang X; Xu Y; Zong Z; Cai J; Chen C; Zhang Q; Sun X; Li J
    Bioorg Med Chem; 2022 Jun; 64():116765. PubMed ID: 35477061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput screening of potassium-competitive acid blockers.
    Kondo M; Kawamoto M; Hasuoka A; Kajino M; Inatomi N; Tarui N
    J Biomol Screen; 2012 Feb; 17(2):177-82. PubMed ID: 21940711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers.
    Nishida H; Hasuoka A; Arikawa Y; Kurasawa O; Hirase K; Inatomi N; Hori Y; Sato F; Tarui N; Imanishi A; Kondo M; Takagi T; Kajino M
    Bioorg Med Chem; 2012 Jun; 20(12):3925-38. PubMed ID: 22579619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soraprazan: setting new standards in inhibition of gastric acid secretion.
    Simon WA; Herrmann M; Klein T; Shin JM; Huber R; Senn-Bilfinger J; Postius S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):866-74. PubMed ID: 17369284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).
    Shin JM; Inatomi N; Munson K; Strugatsky D; Tokhtaeva E; Vagin O; Sachs G
    J Pharmacol Exp Ther; 2011 Nov; 339(2):412-20. PubMed ID: 21828261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2'-piperidin)-1-ones as potassium-competitive acid blockers.
    Imaeda T; Ono K; Nakai K; Hori Y; Matsukawa J; Takagi T; Fujioka Y; Tarui N; Kondo M; Imanishi A; Inatomi N; Kajino M; Itoh F; Nishida H
    Bioorg Med Chem; 2017 Jul; 25(14):3719-3735. PubMed ID: 28522264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling, design, synthesis, and biological activity of 1H-pyrrolo[2,3-c]pyridine-7-amine derivatives as potassium-competitive acid blockers.
    Arikawa Y; Hasuoka A; Hirase K; Inatomi N; Sato F; Hori Y; Takagi T; Tarui N; Kawamoto M; Kajino M
    Chem Pharm Bull (Tokyo); 2014; 62(4):336-42. PubMed ID: 24695343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
    Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
    J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors?
    Kinoshita Y; Ishimura N; Ishihara S
    Am J Gastroenterol; 2018 Oct; 113(10):1417-1419. PubMed ID: 29955116
    [No Abstract]   [Full Text] [Related]  

  • 19. Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).
    Bailey N; Bamford MJ; Brissy D; Brookfield J; Demont E; Elliott R; Garton N; Farre-Gutierrez I; Hayhow T; Hutley G; Naylor A; Panchal TA; Seow HX; Spalding D; Takle AK
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3602-6. PubMed ID: 19467868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gastric H,K ATPase as a drug target: past, present, and future.
    Sachs G; Shin JM; Vagin O; Lambrecht N; Yakubov I; Munson K
    J Clin Gastroenterol; 2007 Jul; 41 Suppl 2(Suppl 2):S226-42. PubMed ID: 17575528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.